Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 2/2015

01.02.2015 | Original Article

Predictive Factors Analysis for Malignant Peritoneal Mesothelioma

verfasst von: Shi Jin, Shoubo Cao, Jingyan Cao, Jing Shen, Jing Hu, Dehai Che, Jiawen Zhang, Yan Yu

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Malignant peritoneal mesothelioma (MPM) is an uncommon disease with a dismal prognosis and unclear natural history. The present study aims to assess potential prognostic factors and management of MPM.

Methods

Clinical records of 39 patients with MPM between December 2003 and April 2014 were retrospectively reviewed. Overall survival was identified with Kaplan-Meier curves and Cox regression analysis.

Results

Mean age of 39 patients was 55.0 years; asbestos exposure was recorded in two patients. Main presentations were abdominal distension, abdominal pain, and weight loss. Thrombocytosis, low serum albumin level, and anemia were principal laboratory abnormalities. Ascites, peritoneal cavity mass, and peritoneum thickening were the main signs on CT scans. Cytoreductive surgery (CRS) plus adjuvant therapies were performed in 22 patients, single chemotherapy in 13, and best supportive care in 4. Median survival time was 10.0 months after pathological diagnosis, with a 6-, 12-, 18-, and 24-month survival rate of 84.4, 31.6, 18.5, and 15.8 %, respectively. Significant prognostic factors were age, performance status (PS), abdominal pain, serum albumin level, thrombocytosis, and treatment strategy on univariate analysis, while only age, abdominal pain, and treatment strategy hold statistical significance on multivariate analysis.

Conclusions

Age ≤65 years, abdominal pain, and CRS plus adjuvant therapy are independent positive prognostic factors of MPM.
Literatur
2.
3.
Zurück zum Zitat Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case–control study. Lung Cancer 2008;61:235–243.PubMedCrossRef Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case–control study. Lung Cancer 2008;61:235–243.PubMedCrossRef
4.
Zurück zum Zitat Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. EJSO 2006;32:676–681.PubMedCrossRef Garcia-Carbonero R, Paz-Ares L. Systemic chemotherapy in the management of malignant peritoneal mesothelioma. EJSO 2006;32:676–681.PubMedCrossRef
6.
Zurück zum Zitat Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000;87:1587–1593.PubMedCrossRef Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000;87:1587–1593.PubMedCrossRef
8.
Zurück zum Zitat Cunha P, Luz Z, Seves I, Sousa C, Skiappa, Ribeiro L, Marques C, Oliveira M. Malignant peritoneal mesothelioma-diagnostic and therapeutic difficulties. Acta Med Port 2002;15:383–386.PubMed Cunha P, Luz Z, Seves I, Sousa C, Skiappa, Ribeiro L, Marques C, Oliveira M. Malignant peritoneal mesothelioma-diagnostic and therapeutic difficulties. Acta Med Port 2002;15:383–386.PubMed
9.
Zurück zum Zitat Sharma H, Bell I, Schofield J, Bird G. Primary peritoneal mesothelioma: case series and literature review. Clin Res Hepatol Gastroenterol 2011;35:55–59.PubMedCrossRef Sharma H, Bell I, Schofield J, Bird G. Primary peritoneal mesothelioma: case series and literature review. Clin Res Hepatol Gastroenterol 2011;35:55–59.PubMedCrossRef
10.
Zurück zum Zitat Piazza D, Caruso F, Scaringi S, Ferrara M, Latteri F, Dell’Erba D. Primary diffuse malignant peritoneal mesothelioma: case report and update of therapy. J Surg Oncol 2000;75:55–58.PubMedCrossRef Piazza D, Caruso F, Scaringi S, Ferrara M, Latteri F, Dell’Erba D. Primary diffuse malignant peritoneal mesothelioma: case report and update of therapy. J Surg Oncol 2000;75:55–58.PubMedCrossRef
11.
Zurück zum Zitat Tan GH, Cheung M, Chanyaputhipong J, Soo KC, Teo MC. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma. Ann Acad Med Singapore 2013;42:291–296.PubMed Tan GH, Cheung M, Chanyaputhipong J, Soo KC, Teo MC. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma. Ann Acad Med Singapore 2013;42:291–296.PubMed
12.
Zurück zum Zitat Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL. Diffuse malignant peritoneal mesothelioma-an update on treatment. Cancer Treat Rev 2012;38:605–612.PubMedCrossRef Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL. Diffuse malignant peritoneal mesothelioma-an update on treatment. Cancer Treat Rev 2012;38:605–612.PubMedCrossRef
13.
Zurück zum Zitat Magge D, Zenati MS, Austin F, Mavanur A, Sathaiah M, Ramalingam L, Jones H, Zureikat AH, Holtzman M, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol 2014;21:1159–1165.PubMedCrossRef Magge D, Zenati MS, Austin F, Mavanur A, Sathaiah M, Ramalingam L, Jones H, Zureikat AH, Holtzman M, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol 2014;21:1159–1165.PubMedCrossRef
14.
Zurück zum Zitat Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 2013;49:3140–3148.PubMedCrossRef Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 2013;49:3140–3148.PubMedCrossRef
15.
Zurück zum Zitat Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori 2003;89:269–273.PubMed Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori 2003;89:269–273.PubMed
16.
Zurück zum Zitat Damhuis RA, Schroten C, Burgers JA. Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Eur Respir J 2012;40:185–189.PubMedCrossRef Damhuis RA, Schroten C, Burgers JA. Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Eur Respir J 2012;40:185–189.PubMedCrossRef
17.
Zurück zum Zitat Cao C, Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH; Peritoneal Surface Malignancy Group. Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol 2012;23:1494–1498.PubMedCrossRef Cao C, Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH; Peritoneal Surface Malignancy Group. Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol 2012;23:1494–1498.PubMedCrossRef
18.
Zurück zum Zitat Park JY, Kim KW, Kwon HJ, Park MS, Kwon GY, Jun SY, Yu ES. Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis. AJR Am J Roentgenol 2008;191:814–825.PubMedCrossRef Park JY, Kim KW, Kwon HJ, Park MS, Kwon GY, Jun SY, Yu ES. Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis. AJR Am J Roentgenol 2008;191:814–825.PubMedCrossRef
19.
Zurück zum Zitat Manzini Vde P, Recchia L, Cafferata M, Porta C, Siena S, Giannetta L, Morelli F, Oniga F, Bearz A, Torri V, Cinquini M. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol 2010;21:348–353.PubMedCrossRef Manzini Vde P, Recchia L, Cafferata M, Porta C, Siena S, Giannetta L, Morelli F, Oniga F, Bearz A, Torri V, Cinquini M. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol 2010;21:348–353.PubMedCrossRef
20.
Zurück zum Zitat Iversen LH, Rasmussen PC, Laurberg S. Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Br J Surg 2013;100:285–292.PubMedCrossRef Iversen LH, Rasmussen PC, Laurberg S. Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Br J Surg 2013;100:285–292.PubMedCrossRef
21.
Zurück zum Zitat Wang J, Gao L, Tang S, Li T, Lei Y, Xie H, Liang J, Chen B, Wang X, Fan D. A retrospective analysis on the diagnostic value of ultrasound-guided percutaneous biopsy for peritoneal lesions. World J Surg Oncol 2013;11:251.PubMedCentralPubMedCrossRef Wang J, Gao L, Tang S, Li T, Lei Y, Xie H, Liang J, Chen B, Wang X, Fan D. A retrospective analysis on the diagnostic value of ultrasound-guided percutaneous biopsy for peritoneal lesions. World J Surg Oncol 2013;11:251.PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Krasuski P, Poniecka A, Gal E. The diagnostic challenge of peritoneal mesothelioma. Arch Gynecol Obstet 2002;266:130–132.PubMedCrossRef Krasuski P, Poniecka A, Gal E. The diagnostic challenge of peritoneal mesothelioma. Arch Gynecol Obstet 2002;266:130–132.PubMedCrossRef
23.
Zurück zum Zitat Chen LY, Huang LX, Wang J, Qian Y, Fang LZ. Malignant peritoneal mesothelioma presenting with persistent high fever. J Zhejiang Univ Sci B 2011;12:381–384.PubMedCentralPubMedCrossRef Chen LY, Huang LX, Wang J, Qian Y, Fang LZ. Malignant peritoneal mesothelioma presenting with persistent high fever. J Zhejiang Univ Sci B 2011;12:381–384.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Turner K, Varghese S, Alexander HR Jr. Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. J Natl Compr Canc Netw 2012;10:49–57.PubMed Turner K, Varghese S, Alexander HR Jr. Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. J Natl Compr Canc Netw 2012;10:49–57.PubMed
26.
Zurück zum Zitat Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006;32:948–953.PubMedCrossRef Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol 2006;32:948–953.PubMedCrossRef
27.
Zurück zum Zitat Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009;27:6237–6242.PubMedCrossRef Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009;27:6237–6242.PubMedCrossRef
28.
Zurück zum Zitat O’Brien ME, Watkins D, Ryan C, Priest K, Corbishley C, Norton A, Ashley S, Rowell N, Sayer R. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 2006;17:270–275.PubMedCrossRef O’Brien ME, Watkins D, Ryan C, Priest K, Corbishley C, Norton A, Ashley S, Rowell N, Sayer R. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 2006;17:270–275.PubMedCrossRef
29.
Zurück zum Zitat Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol 2008;26:3567–3572.PubMedCrossRef Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol 2008;26:3567–3572.PubMedCrossRef
30.
Zurück zum Zitat Cao SB, Jin S, Cao JY, Shen J, Zhang JW, Yu Y. Colonic invasion induced by malignant peritoneal mesothelioma. Int J Colorectal Dis 2014;29:891–892.PubMedCrossRef Cao SB, Jin S, Cao JY, Shen J, Zhang JW, Yu Y. Colonic invasion induced by malignant peritoneal mesothelioma. Int J Colorectal Dis 2014;29:891–892.PubMedCrossRef
Metadaten
Titel
Predictive Factors Analysis for Malignant Peritoneal Mesothelioma
verfasst von
Shi Jin
Shoubo Cao
Jingyan Cao
Jing Shen
Jing Hu
Dehai Che
Jiawen Zhang
Yan Yu
Publikationsdatum
01.02.2015
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 2/2015
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-014-2664-4

Weitere Artikel der Ausgabe 2/2015

Journal of Gastrointestinal Surgery 2/2015 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.